Blueprint Medicines lays out growth plans

Blueprint Medicines Corporation (NASDAQ:BPMC) formally sets out its corporate goals for 2020.

“As we complete our evolution into a fully-integrated biopharmaceutical company this year, we will also aim to bring a second product to market, expand across multiple indications and extend our global commercial footprint with our first anticipated regulatory approval in Europe.”

The company says its future growth will also be fueled by an expanded strategic focus on systemic mastocytosis and related mast cell disorders, which represent a large population of underserved patients with significant medical needs.

In particular, Blueprint expects to report top-line data from the Phase 3 VOYAGER trial of avapritinib in third-line GIST in Q2 and gain regulatory approval and launch avapritinib in fourth-line GIST in the U.S. During Q3, the company aims to gain regulatory approval and launch avapritinib in PDGFRA D842V GIST in Europe.

#JPM20

Source: Press Release

https://seekingalpha.com/news/3531264-blueprint-medicines-lays-out-growth-plans